We performed extensive characterization of NR-V04 and revealed it to have a promising pharmacokinetic (PK) and pharmacodynamic (PD) profile, degradation efficiency and specificity for NR4A1, tumor-inhibitory effect, and immune activation within the TME, along with its low toxicity within the therapeutic dosing range. Here, NR4A1 is linked to neoplasm.